Commercial disputes under international arbitration between multinational firms often require assessing the impact of commercial strategy, planning and execution. In the biopharmaceutical industry, these disputes often center on failed co-development, co-marketing, and co-promotion agreements, typically as a result of one party asserting that the other has not performed according to the agreement. In this article, we outline how the building blocks of market intelligence can be used to assist in the evaluation of such claims.
Risks to onshore and offshore wind projects from new US Administration orders
On January 20, 2025 the new US Administration released a memorandum with important implications for the US wind industry, temporarily preventing the...